Tumor Type

Australia
Pancreatic Cancer - Endocrine neoplasms
www.pancreaticcancer.net.au  HTML www.pancreaticcancer.net.au  HTML
Project Profile
Funding Organizations
Research Organizations
Research Activities
Publication Policy

1:   ICGC Goals, Structure, Policies and Guidelines Section E.3 - Publication Policy HTML 
2:   Template Letters to Facilitate Communications HTML 
to ensure appropriate dialogue between data users and generators and for authors to contact ICGC members and editors
Clinic & Pathology

Australia: Australian Pancreatic Cancer Genome Initiative
Garvan Institute of Medical Research
Peter MacCallum Cancer Centre
United States: Baylor College of Medicine, Elkins Pancreas Center

Sample acquisition, management and processing will be conducted through the Australian Pancreatic Cancer Genome Initiative (APGI), based at the Garvan Institute of Medical Research, Sydney. The APGI brings together the expertise of pancreatic cancer scientists and healthcare professionals across Australia, and is dedicated to improving outcomes for pancreatic cancer patients and their families.

The APGI has established international collaborations with Baylor College of Medicine, specifically Drs. Richard Gibbs, David Wheeler, Marie-Claude Gingras and Bill Fisher, will contribute on the scientific, analysis and clinical fronts respectively.

1:   Participant Information and Consent Form PDF 
2:   APGI Synopsis PDF 
Sequencing & Analysis

Australia: Institute for Molecular Bioscience
Queensland Centre for Medical Genomics
United States: Human Genome Sequence Center, Baylor College of Medicine
Complementary Studies

Australia: Garvan Institute of Medical Research
Data Storage, Analysis & Management

Australia: Garvan Institute of Medical Research
Institute for Molecular Bioscience
Project Summary

Pancreatic Endocrine Neoplasms are rare in comparison with tumors of the exocrine pancreas, accounting for only 2% of all pancreatic neoplasms. They may be benign or malignant with the ability to spread to the liver and lymph nodes, and it is often difficult to predict the biologic behaviour of these neoplasms. As a complimentary effort to our Pancreatic Ductal Adenocarcinoma project, we aim to explore the genomic and transcriptomic landscape of pancreatic endocrine neoplasms using high quality tumor and normal tissue samples acquired as part of the Australian Pancreatic Cancer Genome Initiative (APGI). Genomic information will be correlated with comprehensive clinico-pathological, treatment and outcome data acquired prospectively.

Principal Investigators

• Andrew Biankin
• Sean Grimmond
• Nic Waddell
• Amber Johns

Lead Jurisdiction